ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: View All • a b c d e f g h i j k [l] m n o p q r s t u v w x y z

Abstract Number: 0314

Lack of Systemic Effects from Intra-articular XT-150 for the Treatment of Moderate to Severe Pain Due to OA of the Knee: Safety Results from a Phase 2 Trial
Abstract Number: 2387

Large Vessel Involvement and the Risk of Severe Infections in Patients with Giant Cell Arteritis – a Population-based Study
Abstract Number: 1538

Large Vessel Involvement in Antineutrophil Cytoplasmic Antibody- Associated Vasculitis: A Single Center Experience over Two Decades
Abstract Number: 0702

Large Vessel Vasculitis Increases Risk of Acute Myocardial Infarction in Patients Admitted for Congestive Heart Failure : A Nationwide Inpatient Database Study
Abstract Number: 2513

Latent Class Analysis Identifies 2 Clinical Phenotypes of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
Abstract Number: 0388

Left Ventricular Geometry Abnormalities Are Related to Higher Clinical Activity in Rheumatoid Arthritis Patients
Abstract Number: 0812

Length of Synovial Fluid Monosodium Urate Crystals According to Sonographic Articular Deposits: Advancing in the Crystallization Process
Abstract Number: 2099

Lesser Impact of Lower-Small Joint Involvement on Pain Than Upper-Small Joint in Rheumatoid Arthritis: Analysis Based on a Large Rheumatoid Arthritis Database in Japan
Abstract Number: 0147

Leukotriene Inhibitors Effect on Post-Traumatic Osteoarthritis: A Real-World Evidence Comparative Effectiveness Study
Abstract Number: 0494

Levels of Atherosclerotic Index of Plasma and Triglyceride Glucose Index in Patients with Psoriatic Arthritis and Carotid Plaque
Abstract Number: 2324

Leveraging ChatGPT for Real-World Systematic Lupus Erythematosus Data Curation from Electronic Health Records: A Feasibility Study
Abstract Number: 1012

Leveraging Cues and Rewards to Form Habits to Improve Medication Adherence in Gout: An Adaptive Behavioral Pilot Trial
Abstract Number: 0196

Limited Regulatory T Cell Response in Post-Chikungunya Viral Arthritis: A Therapeutic Opportunity?
Abstract Number: 2137

Line of Therapy of Biologics and JAK Inhibitors in RA, PsA and AxSpA: Implications for Design and Uptake of New Drugs and Diagnostics
Abstract Number: 0895

Lipocalin-2 Promotes Cutaneous and Neuropsychiatric Disease in Murine Lupus
Abstract Number: 0598

Litifilimab Modulates Type I IFN Biomarkers in Patients with SLE or CLE in the Phase 2 LILAC Study
Abstract Number: 0762

Liver Disease Is a Common Feature of HA20 That Causes Significant Morbidity Associated with Interferon Induction
Abstract Number: 0801

LncRNA PIGL-217 Regulates Th17 Differentiation by Targeting miR-5008-5p and Suppressing FoxO1 in Behçet’s Disease
Abstract Number: 1250

Local Inflammatory Response Mediated by the Homing of Tfh17 Cells Is Involved in Tissue Injury of Immunoglobulin a Vasculitis
Abstract Number: 0152

Long Covid in Persons with Self-Reported Arthritis – Symptoms, Associated Factors and Functional Limitations
Abstract Number: 0588

Long Term Safety and Predictors of Serious Infections Among Patients with Systemic Lupus Erythematosus Treated with Rituximab: Audit from a Single Center Biologic Registry
Abstract Number: 0355

Long Term Safety of Drugs in Systemic Juvenile Idiopathic Arthritis
Abstract Number: 1383

Long-term Association Between Physical Activity and Global Functioning in Patients with axSpA: Results of a 2 Year Prospective Study
Abstract Number: 1165

Long-term Changes in Lung Function in Melanoma Differentiation-associated Protein 5 (MDA5) Antibody Positive Dermatomyositis Patients: Experience of a Single Center Longitudinal Cohort in North America
Abstract Number: 0451

Long-term Clinical Profile of Filgotinib in Patients with Rheumatoid Arthritis by Cardiovascular Risk Factors: A Post Hoc Subgroup Analysis
Abstract Number: 0317

Long-term Effectiveness of a Lifestyle Program for Osteoarthritis: One-year Follow-up of the “Plants for Joints” Randomized Clinical Trial
Abstract Number: 1331

Long-term Effectiveness of a Lifestyle Program for Rheumatoid Arthritis: One-year Follow-up of the “Plants for Joints” Randomized Clinical Trial
Abstract Number: 2166

Long-Term Effects of Abatacept on Arthritis and Atherosclerosis in Older vs Younger Patients with Rheumatoid Arthritis: 3-year Results of a Prospective, Multicenter, Observational Study
Abstract Number: 1572

Long-term Efficacy and Retention Rate of Molecular Targeted Drugs in Takayasu Arteritis
Abstract Number: 1434

Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 2 Trial
Abstract Number: 1435

Long-Term Efficacy and Safety of Risankizumab for CsDMARD-IR Patients with Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 1 Trial
Abstract Number: 1868

Long-term Efficacy of a 2-year MRI Treat-to-target Strategy on Radiographic Joint Damage Progression in Rheumatoid Arthritis Patients in Clinical Remission – Five Year Follow-up of the IMAGINE-RA Randomized Clinical Trial
Abstract Number: 0854

Long-term Efficacy of Remission-induction Regimens for Eosinophilic Granulomatosis with Polyangiitis
Abstract Number: 2225

Long-term Evolution of Spondyloarthritis Patients Included in REGISPONSER, 17 Years Later (REGISPON-3 Study)
Abstract Number: 1273

Long-term Follow-up of Treated-to-target RA and UA: Results of the BeSt and IMPROVED Studies
Abstract Number: 1850

Long-term Glucocorticoid Use in a Cohort of Elderly Early Rheumatoid Arthritis Patients: A Joint Analysis of Medicare and the Rheumatology Informatics System for Effectiveness (RISE) Data
Abstract Number: 1537

Long-term Observational Study of Interstitial Lung Disease in ANCA-associated Vasculitis
Abstract Number: 0307

Long-term Prognosis and Recurrence in anti-MDA-5 Antibody-positive Dermatomyositis
Abstract Number: 0519

Long-Term Safety and Efficacy of Bimekizumab in Patients with Active Ankylosing Spondylitis: 5-Year Results from a Phase 2b Study and Its Open-Label Extension
Abstract Number: 1505

Long-term Safety and Efficacy of Voclosporin in Black Patients with Lupus Nephritis: Results from the AURORA 1 and AURORA 2 Studies
Abstract Number: 0511

Long-term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Results from Pooled Phase 2b/3 Studies
Abstract Number: 1422

Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: Integrated Analysis of Psoriasis and Psoriatic Arthritis Clinical Trial Data
Abstract Number: 0679

Long-term Safety of Rituximab (Mabthera) in Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA): Rituximab Surveillance Study in VASculitis (RIVAS)
Abstract Number: 0425

Long-term Safety of Rituximab in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Abstract Number: 1533

Long-term Use of Rituximab in Systemic Sclerosis: A Real-life Italian Multicentre Study
Abstract Number: 2325

Longitudinal ANA Titers in SLE and ANA-associated Rheumatic Diseases
Abstract Number: 1229

Longitudinal Assessment of Self-reported Executive Function in Youth with Childhood-Onset Lupus
Abstract Number: 1805

Longitudinal Changes in Serum Urate Associate Minimally with Changes in Daily Alcohol Intake
Abstract Number: 2271

Longitudinal Changes in Type 1 & Type 2 SLE Activity
Abstract Number: 2238

Longitudinal Effect of Guselkumab on Biomarkers of Inflammation and Cardiovascular Risk in Bionaive Patients with Active Psoriatic Arthritis and High Systemic Inflammatory Burden: Post-hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-Controlled Study
Abstract Number: 0557

Longitudinal Evaluation of Cell-bound Complement Activation Products in Patients with SLE
Abstract Number: 1429

Longitudinal Evaluation of the Novel Psoriatic Arthritis 5-Thermometer Scale (PsA-5Ts) Domains During Treatment with Guselkumab: Pooled Analysis of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
Abstract Number: 0339

Longitudinal Glucocorticoid Toxicity in Rheumatic Disease Patients (LONG-TOX) and Associations with Quality of Life and Healthcare Resource Utilization: Interim Analysis from a Prospective Cohort
Abstract Number: 2433

Longitudinal Multi-Omics Single Cell Analysis Reveals Abatacept Treatment Shifts Peripheral Lymphocyte Subpopulations in Seropositive RA with Reduction of Mature B Cells and Retention of Transitional and Naive B Cells
Abstract Number: 1718

Longitudinal Quantification of Bone Erosions, Pulmonary Disease, Pain, Gait and Sarcopenia to Holistically Assess Decreased Ad Libitum Physical Activity and Effects of Exercise in the TNF-Transgenic Murine Model of Rheumatoid Arthritis
Abstract Number: 0210

Longitudinal T Cell Responses to a Series of Four SARS-CoV-2 Vaccine Doses or COVID-19 in Patients on TNF Inhibitors
Abstract Number: 2378

Longitudinal Trajectories of Renal Function in ANCA-Associated Vasculitis: Findings from the Expanded Mass General Brigham Cohort
Abstract Number: 0230

Looking Beyond Infections in Job Syndrome: Peripheral Calcium Pyrophosphate Deposition Disease in a Cohort of Patients with Job Syndrome
Abstract Number: 0001

Loss of the Complement Regulator CD55 Alters Marginal Zone B Cell Homeostasis
Abstract Number: 0877

Loss of Transient Receptor Potential Channel 1 (TRPC1) Links Regulation of Intracellular Calcium to Cellular Senescence and Leads to Development of Osteoarthritis
Abstract Number: 0842

Low Rate of Switching from Nr-axSpA to r-axSpA After 10 Years of Follow up in Early Axialspondyloarthritis. Data from DESIR Cohort
Abstract Number: 2470

Low Serum Adiponectin Levels Were Associated with Radiographic Progression of Hand Osteoarthritis in a 6-year Follow-up of the Dong-gu Study
Abstract Number: 1389

Low Spinal Radiographic Progression After a Mean of 15 Years of Follow-up in a Cohort of Patients with Axial Spondyloarthritis
Abstract Number: 2548

Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials
Abstract Number: 0781

Low vs. High Initial Oral Glucocorticoid Dose for Lupus Nephritis Induction Treatment: A Pooled Analysis of Randomized Controlled Clinical Trials
Abstract Number: 0905

Low-Density Granulocytes and Neutrophil Extracellular Traps in Incomplete Systemic Lupus Erythematosus
Abstract Number: 1267

Lower Herpes Zoster Rate of Tocilizumab and Tofacitinib in Patients Undergoing Treatment for Rheumatoid Arthritis
Abstract Number: 1022

Lower Rates of Statin Therapy Initiation in Dermatomyositis/Polymyositis vs. Rheumatoid Arthritis Patients with Hyperlipidemia: A Multicenter USA-Based Study (2018-2023)
Abstract Number: 2188

Lung Cysts in Primary SS: New Findings on an Allegedly Innocuous Iiagnosis
Abstract Number: 2265

Lupus Damage Index Revision – Item Generation and Reduction Phase
Abstract Number: 1464

Lupus Flares More Common in Patients on Dialysis Compared to After Renal Transplant: A Systematic Review and Meta-analysis
Abstract Number: 1501

Lupus Low Disease Activity State (LLDAS) Achievement with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in SLE
Abstract Number: 2275

Lupus Low Disease Activity State Ameliorates the Poor Prognosis in Lupus Nephritis Patients with anti-Sm Autoantibody
Abstract Number: 2274

Lupus Low Disease Activity State as an Attainable Target in Lupus Nephritis Associated with Reduced Risk of Relapse
Abstract Number: 0851

Lupus Nephritis Flares Linked to Platelet Activation During Gut Pathobiont Blooms
Abstract Number: 2017

Lupus Nephritis Is Strongly Associated with Low Bone Mineral Density and Osteoporosis in Patients with Systemic Lupus Erythematosus
Abstract Number: 0593

Lupus Nephritis of the Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus
Abstract Number: 2456

Lupus Patient Navigator Program to Improve Healthcare Barriers for Minority Patients
Abstract Number: 1652

Lupus Research Action Network: Increasing Minority Clinical Trial Participation Through Peer Leaders
Abstract Number: PP03

Lupus with Slime: Improve QOL and Increase ROM in SLE with Slime
Abstract Number: 0255

Lymphoid Mass in the Inferior Turbinate with IgG4 Producing Cells: A Nasal Manifestation of IgG4-RD or a Distinct Chronic Inflammatory Disease?
Abstract Number: 2189

Lymphopenia Fluctuation Patterns Determine the Trajectory of the Disease in Sjogren’s Patients with Hematological Involvement

Jump to: View All • a b c d e f g h i j k [l] m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].